Extensively drug-resistant Pseudomonas aeruginosa: Risk of bloodstream infection in hospitalized patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 10, 2012, Pages 2791-2797

  Pena C ^a   Gomez Zorrilla S ^a   Suarez, C ^a   Dominguez, M A ^a   Tubau, F ^a   Arch, O ^a   Oliver, A ^b   Pujol, M ^a   Ariza, J ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM COLONY; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CLONAL VARIATION; CONTROLLED STUDY; FEMALE; GENETIC HETEROGENEITY; HOSPITAL PATIENT; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PULSED FIELD GEL ELECTROPHORESIS; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CONFIDENCE INTERVALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; FLUOROQUINOLONES; GENETIC HETEROGENEITY; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 84869121218     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1629-3     Document Type: Article

References (30)

1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268-281. doi:10.1111/j.1469-0691. 2011.03570.x
2. Troillet N, Samore MH, Carmeli Y (1997) Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 25:1094-1098
3. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y (1999) Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 28:1128-1133
4. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH (1999) Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43:1379-1382
5. El Amari EB, Chamot E, Auckenthaler R, Pechère JC, van Delden C (2001) Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 33:1859-1864
6. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC (2002) Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 34:340-345
7. Cao B, Wang H, Sun H, Zhu Y, Chen M (2004) Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa. J Hosp Infect 57:112-118
8. Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daurès JP et al (2004) Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 57:209-216
9. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50:43-48
10. Philippe E, Weiss M, Shultz JM, Yeomans F, Ehrenkranz NJ (1999) Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment. Clin Perform Qual Health Care 7:83-87
11. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL et al (2004) Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 38:670-677
12. Carmeli Y, Troillet N, Karchmer AW, Samore MH (1999) Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 159:1127-1132
13. Giamarellos-Bourboulis EJ, Plachouras D, Tzivra A, Kousoulas V, Bolanos N, Raftogiannis M et al (2004) Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study. Clin Exp Immunol 138:240-246
14. Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH (2011) Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother 66:1311-1317
15. Hocquet D, Berthelot Ph, Roussel-Delvallez M, Favre R, Jeannot K, Bajolet O et al (2007) Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother 51:3531-3536
16. Paterson DL, Doi Y (2007) A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 45:1179-1181
17. Falagas ME, Karageorgopoulos DE (2008) Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 46:1121-1122
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383
19. Clinical and Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing; Nineteenth informational supplement. CLSI document M100-S19. CLSI, Wayne, PA; vol. 29, no. 3
20. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2008) Breakpoint tables for interpretation of MICs and zone diameters (updated 27 April 2010; last accessed 29 October 2010). Available online at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-Test-documents/ EUCAST-breakpoints-v1.1
21. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH et al (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233-2239
22. Peña C, Suarez C, Tubau F, Juan C, Moya B, Dominguez MA et al (2009) Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 ß-lactamase. J Clin Microbiol 47:2381-2387
23. Suarez C, Peña C, Arch O, Dominguez MA, Tubau F, Juan C et al (2011) A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infect Dis 11:272-279
24. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP et al (2002) Health care-Associated bloodstream infections in adults: a reason to change the accepted definition of community-Acquired infections. Ann Intern Med 137:791-797
25. Tumbarello M, Repetto E, Trecarichi EM, Bernardini C, de Pascale G, Parisini A et al (2011) Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 139:1740-1749
26. Poole K (2000) Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. Antimicrob Agents Chemother 44:2233-2241
27. López-Dupla M, Martínez JA, Vidal F, Almela M, Soriano A, Marco F et al (2009) Previous ciprofloxacin exposure is associated with resistance to ß-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control 37:753-758
28. Murphy TF (2009) Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 15:138-142
29. Maciá MD, Blanquer D, Togores B, Sauleda J, Pérez JL, Oliver A (2005) Hypermutation is a key factor in development of multipleantimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 49:3382-3386
30. Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM et al (2000) Effect of antibiotic therapy on the density of vancomycin-resistant Enterococci in the stool of colonized patients. N Engl J Med 343:1925-1932